Where time, place,
and minds align.

Technology

Intersection of Science,
Medicine and AI

Structured as an asset-driven biopharma company, Artemis advances its own therapeutic programs to capture the full value of innovation while maintaining strategic focus and scientific integrity. Its leadership team and Scientific Advisory Board include globally recognized pioneers in AI-enabled drug discovery, oncology, and translational medicine — bridging visionary science with disciplined execution.

Rooted in a heritage of learning and scientific rigor, and through our partnership with the University of British Columbia, Artemis honours the long arc of discovery — knowing that timing matters as much as insight.

Meeting the People leading Artemis

  • Frank
    Holler

    CEO & Executive Chairman

    Frank
    Holler

    CEO & Executive Chairman

    Founder and CEO of ID Biomedical, acquired by GSK for $1.6 billion, Founding director of Angiotech Pharmaceuticals, Founder and CEO of Xenon Pharmaceuticals, a US $3.5 billion NASDAQ-listed company. Life Science BC Leadership Award winner.

  • Artem
    Cherkasov, PhD

    Co-Founder & CTO

    Artem
    Cherkasov, PhD

    Co-Founder & CTO

    Professor of Medicine, University of British Columbia, Tier 1 Canada Research Chair in Precision Cancer Drug Discovery, Authored 200+ research papers in computational chemistry, machine learning and AI, awarded $100+ million in research grants, 3 drug candidates advanced into clinical trials.

  • Mads
    Daugaard, PhD

    Co-Founder & CEO

    Mads
    Daugaard, PhD

    Co-Founder & CEO

    Professor of Medicine, University of British Columbia, Senior Research Scientist and Head, Molecular Pathology at Vancouver Prostate Centre, Co-inventor and developer of multiple drug candidates (SnapCyte, VAR2).

  • Rick
    Huang

    CFO

    Rick
    Huang

    CFO

    Seasoned finance executive with broad experience in corporate finance, capital markets, M&A, IFRS/GAAP reporting, and financial strategy. Rick is a CPA and holds an MBA from the Ivey Business School at Western University.

Artemis brings together leaders in computational science, translational medicine, and biotechnology to accelerate the future of therapeutic discovery.

Advisory Board

  • Alex
    Tropsha, Dr.

    Alex
    Tropsha, Dr.

    KH Lee Distinguished Professor, University of North Carolina - Chapel Hill Eshelman School of Pharmacy, global leader in drug discovery research specializing in cheminformatics and quantitative structure-activity relationship (QSAR) modeling, Elected Fellow, The American Institute for Medical and Biological Engineering (AIMBE)

  • Poul
    Sorenson, Dr.

    Poul
    Sorenson, Dr.

    Professor of Medicine, University of British Columbia, Johal Endowed Chair in Childhood Cancer Research, Director of Academy of Translational Medicine at UBC, Winner of Doctors of BC Terry Fox Medal, Dr. Wei Memorial Prize in Cancer Research, Bloom Burton Award for innovative cancer research

  • S. Larry
    Goldenberg, Dr.

    S. Larry
    Goldenberg, Dr.

    Professor, Department of Urologic Sciences, University of British Columbia; former Head of the Department (2000–2014) and founding Director of the Vancouver Prostate Centre. Chairman of the Canadian Men’s Health Foundation and co-founder of the Canadian Uro-Oncology Group. Author of 400+ peer-reviewed publications. Recipient of the Order of Canada, Order of British Columbia, and multiple lifetime achievement awards in urologic oncology